Ibuprofen Improves Cerebral Blood Flow After Global Cerebral Ischemia in Dogs
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In a canine model of global cerebral ischemia, 6 dogs received a saline placebo prior to the event and 5 received 12.5 mg/kg ibuprofen. Cerebral venous outflow from the confluence of the sagittal and transverse sinuses, systolic and diastolic arterial pressure, cardiac output, pH, Pacoj, Pao 2 , and arterial and sagittal sinus thromboxane B } and 6-keto-PGF, a were measured at intervals up to 120 minutes thereafter. Postischemic cerebral hypoperfusion was significantly unproved in the ibuprofen pretreatment group. Control dogs showed significant increases in sagittal sinus postischemic thromboxane B 2 concentrations, but pretreated dogs showed nearly complete inhibition of postischemic thromboxane B 2 production. Pretreated dogs also had significantly lower levels of 6-keto-PGF )a from the sagittal sinus. There were no significant differences in the other variables at any interval. We conclude that ibuprofen ameliorates postischemic cerebral hypoperfusion, and that this improvement is associated with decreased sagittal sinus levels of thromboxane B 2 and 6-keto-PGF, a . (Stroke 1987; 18:787-791)
T he incidence of neurologic morbidity and mortality following successful resuscitation from cardiac arrest remains distressingly high. Recently, the Brain Resuscitation Clinical Trial I Study Group documented that only 15-20% of patients hemodynamically resuscitated from cardiac arrest eventually survived with "good" cerebral recovery.
1
Among patients who are comatose after resuscitation, only 13% regain independent function.
2 Any improvement in cerebral resuscitation following global cerebral ischemia would be clinically and economically important.
In animals that have sustained global cerebral ischemia followed by restoration of cerebral perfusion, transient cerebral hyperemia is followed by prolonged hypoperfusion, which is associated with progressive neurologic damage.
3 Selected agents that increase postischemic cerebral blood flow (CBF) have been associated with improved neurologic outcome in primates and dogs.
4 "
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The role of calcium influx and the associated release of eicosanoids appears to be central in the progression of neurologic damage following global ischemia. 37 "
9
The term "eicosanoid" refers to all compounds derived from 20-carbon unsaturated fatty acids (such as arachidonic acid, AA), which include the primary prostaglandins, the cyclic endoperoxides, the prostanoids, the leukotrienes, and other related compounds. 10 The enzymes for eicosanoid biosynthesis are present in ner-vous tissue, vascular tissue, and blood cells. The enzyme phospholipase A 2 , which releases fatty acids (including AA) from cell membranes, is activated by increased calcium levels," and calcium concentration is increased in intracellular fluid during cerebral ischemia. 12 AA is the substrate from which leukotrienes are synthesized by lipoxygenase and related enzymes, and from which prostacyclin (PGI 2 ) and thromboxane A 2 (TxA 2 ) are produced by cyclooxygenase and subsequent enzymes. 13 PGI 2 and TxA 2 have opposing effects on the microvasculature. PGI 2 produces vasodilation and platelet disaggregation, while TxA 2 produces vasoconstriction and platelet aggregation. 10 Infusion of indomethacin to inhibit cyclooxygenase and PGI 2 to produce cerebral vasodilation has been shown to promote postischemic neurologic recovery in rats and dogs. 1415 Potentially neurotoxic mediators, such as superoxides, may also be released in association with the increased metabolism of AA.
1617
Evidence that AA may play a central role in human ischemic neurologic injury is the increased excretion of thromboxane B 2 (TxB 2 ), which is the stable metabolite of TxA 2 , following ischemic stroke in humans. The increased excretion correlates with the severity of the neurologic insult. 18 Marked increases in TxB 2 concentration have also been noted in canine jugular venous blood after global cerebral ischemia."
Ibuprofen is a competitive cyclooxygenase inhibitor that should alter the type and amount of eicosanoids released after global cerebral ischemia. The purpose of this study was to evaluate the effect of pretreatment with ibuprofen on postischemic CBF and on production of TxA 2 and PGI 2 .
Materials and Methods
After approval by the institutional animal care committee, 12 mongrel dogs weighing 15-25 kg were anesthetized with 10-15 mg/kg thiopental i.v. fol-lowed by 1.5 mg/kg succinylcholine. Each dog was endotracheally intubated and ventilated at an Fio 2 of 0.4 and a tidal volume of 12-15 ml/kg at a rate adjusted to produce a Paco 2 of 35-45 mm Hg. Halothane (1.0% in O 2 ) provided maintenance anesthesia until the preparation was completed.
A right femoral arterial catheter was placed percutaneously and connected via a Statham P23Db transducer to a Grass Model 79D oscillograph. A 7.5-Fr pulmonary artery catheter was passed percutaneously through the right external jugular vein using the Seldinger technique. The dog was then placed in the left lateral decubitus position, and a thoracotomy was performed in the fifth interspace. The azygos vein was isolated and ligated. The superior and inferior vena cavas were dissected free, and snares were passed around them and loosely secured. The pericardium was incised, and a large vessel clamp was placed loosely around the aorta at a point immediately proximal to the origin of the brachiocephalic artery.
The thoracotomy wound was loosely approximated and the animal was turned to the prone sphinx position. The posterior occipital muscles were dissected from the cranium using a periosteal elevator and an electrocautery unit. The operative site was frequently irrigated with ice water to prevent thermal injury to the central nervous system. After heparinization, a cannula was inserted into the confluence of the sagittal sinus and the transverse sinuses for blood sampling and cerebral venous outflow measurement. The transverse sinuses were located with a high-speed drill and occluded with bone wax; the occlusion was confirmed by monitoring sagittal sinus pressure during a brief (< 1 second) occlusion of the sagittal sinus outflow. A rise of sagittal sinus pressure to > 50 mm Hg was considered to indicate adequate transverse sinus occlusion. The dog was then returned to the left lateral decubitus position, haJothane was discontinued, and 60% N 2 O:40% O 2 was given for at least 30 minutes.
The following data were collected at intervals to be specified below: CBF (cerebral venous outflow through the sagittal sinus cannulas), systolic and diastolic arterial pressure, cardiac output, pH, Paco 2 , Pao 2 , and heart rate. Blood samples were collected from the sagittal sinus and the systemic arterial catheter for radioimmunoassay (RIA) of TxB 2 and 6-keto-PGF, a (the stable metabolite of PGI 2 ).
Baseline data were collected after the 30-minute rest period noted above. The dog was then assigned in a random, blinded manner to one of two groups: Group 1 (n = 6) received 10 ml of saline i.v., and Group 2 (n = 6) received 12.5 mg/kg of ibuprofen i.v. in 10 ml of saline. Five minutes after injection of the above solutions, simultaneous occlusion of the aorta and vena cavas produced global cerebral ischemia for 10 minutes. After 9 minutes, 30 seconds of occlusion, 1 meq/kg sodium bicarbonate was administered i.v. through a peripheral catheter. No other resuscitative drugs were administered. Sagittal sinus venous outflow data were collected at 1,5, 10, 30, 60, 90, and 120 minutes after release of the occlusion; blood samples for determination of TxB 2 and 6-keto-PGF, a were obtained at 1, 30, 60, 90, and 120 minutes after ischemia; and hemodynamic data were obtained at 5, 30, 60, 90, and 120 minutes after ischemia.
Blood (4.0-ml samples) was withdrawn simultaneously from the aortic and sagittal sinus catheters into sterile disposable syringes, immediately transferred to test tubes containing 0.5% EDTA and 25 /ig indomethacin/ml whole blood, and maintained on ice at 4° C until centrifuged at 1,500g at 4° C for 15 minutes. The plasma was aspirated and placed in polypropylene test tubes, which were then labelled and stored at -20° C. Immunoreactive TxB 2 and 6-keto-PGF| a were assayed directly in plasma by standard doubleantibody RIA techniques. 20 -21 Cross-reactivities and sensitivity limits of these antibodies and reagents have been described. 20 The total duration of the experimental procedure for each dog averaged 4.5 hours, and all dogs were killed 120 minutes after ischemia. Cerebral tissues were examined in pilot dogs to confirm that the experimental preparation itself did not cause gross cerebral injury. Brain histology was otherwise not examined.
All data were analyzed by multivariate analysis of variance (MANOVA), w i t h p < 0 . 0 5 considered significant. Data were analyzed using absolute values and, in the case of the eicosanoid metabolites, using rank order analysis due to skewed distribution of data. Differences at individual time intervals were confirmed by one-tailed t test, with p<0.Q5 considered significant.
Results
Review of RIA data after completing the study showed that 1 treatment dog (Group 2) had extraordinarily high TxB 2 levels after global cerebral ischemia. These values were the highest of all the dogs, approximately 10 times higher than those of the other Group 2 animals, and 2 times higher than those of the Group 1 (control) animals. The reason for this is not clear, but may relate to unrecognized brain injury during the preparation or to inadequate ibuprofen dosage. Since the purpose of the study was to determine the efficacy of cyclooxygenase inhibition in this model and since the cyclooxygenase enzyme obviously was not inhibited in this animal, data from this dog were eliminated from subsequent analysis.
Cerebral venous outflow values during the experiment are shown in Figure 1 and Table 1 . Statistical analysis indicated that the rate of sagittal sinus outflow was significantly dependent on time (p = 0.0035) and that the time effect was significantly different between control and pretreatment groups atp = 0.014. Significantly increased cerebral venous outflow in the ibuprofen group was confirmed by one-tailed t tests at 30, 60, and 90 minutes after occlusion (p = 0.005, 0.03, and 0.05, respectively). At 120 minutes after occlusion, p = 0.07.
In control dogs, immunoreactive TxB 2 measured in sagittal sinus blood increased following release of the aortocaval occlusion and remained increased through- 
FIGURE 1. Cerebral venous outflow as a function of time in the control and ibuprofen-pretreated groups. Both groups demonstrated a transient hyperemia followed by a reduction in cerebral venous outflow rate. The postischemic hypoperfusion was significantly more profound in the control than in the ibuprofen group. Shaded area represents ischemia.
out the 2-hour study period (Figure 2 , Table 1 ). The effect of timeonTxB 2 was significant (p = 0.0001). In contrast, ibuprofen-pretreated dogs had no significant increase in immunoreactive TxB 2 levels in sagittal sinus blood. The interaction between groups and time was significant (p = 0.001), and the difference between sagittal sinus TxB 2 levels in the 2 groups was significant at 30, 60, 90, and 120 minutes after occlusion. Arterial levels of TxB 2 were lower than sagittal sinus levels in control dogs at all intervals ( ly different between pretreated and control dogs. At no interval were arterial levels significantly different from sagittal sinus levels in ibuprofen-pretreated dogs.
Immunoreactive 6-keto-PGF, a levels are shown in Table 1 and Figure 3 . In the series as a whole, the effect of time on the levels of 6-keto-PGF, 0 was significant (p = 0.03). The differences were most marked in sagittal sinus levels in the control dogs, with significant differences (referenced to baseline) occurring immediately after occlusion and at 30, 60, 90, and 120 minutes after ischemia. Arterial levels in the control dogs and arterial and sagittal sinus levels in the ibuprofen-pretreated dogs showed no differences. Sampling site (arterial vs. sagittal sinus) exerted a significant overall effect (p = 0.0077). Sagittal sinus levels were different between groups at all intervals except 1 minute; however, there was an unexplained difference at baseline.
Systolic and diastolic blood pressure, Paco 2 , cardiac output, and heart rate were similar in both groups of dogs at all intervals before and after release of the occlusion (Table 1) . Systolic and diastolic blood pressures quickly returned to control levels in all dogs, usually within 10 minutes after release of the aortocaval occlusion.
Discussion
Ibuprofen given before global ischemia ameliorated postischemic brain hypoperfusion in this canine model. If this finding is confirmed when the drug is given after the ischemic insult, it may have clinical implications for improving neurologic recovery after cardiac arrest. Nimodipine is a calcium entry blocking agent that increases CBF after global cerebral ischemia and has been associated with improved neurologic outcome in primates 4 and dogs. 3 However, the addition of nimodipine to the constant perfusion bath of an in vitro Group 1 (control) n = 6; Group 2 (treatment) n = 5. TxB 2 , thromboxane B 2 . Values are means ± SEM. rat brain slice preparation did not provide protection against anoxia. 22 Results from this study 22 suggest that improved brain perfusion is the cause of the in vivo protective effects of nimodipine. Lidoflazine, another calcium entry blocking agent, does not appear to ameliorate postischemic cerebral hypoperfusion. 23 Despite the suggestion of improvement in neurologic outcome in dogs, 23 a more recent study found no evidence that lidoflazine treatment improved postischemic neurologic outcome in primates (J.E. Fleischer, personal communication). Thus, although definite proof is lacking, the improvement in postischemic CBF appears to be responsible for the improved neurologic outcome.
Calcium influx following an ischemic insult may initiate a catabolic cascade that produces a variety of potentially harmful eicosanoids, including TxA 2 . The cerebral and arterial TxB 2 concentrations in our control dogs indicate that TxA 2 is released in larger quantities from the cerebral vasculature and/or tissues than from the systemic circulation following global cerebral ischemia, and they confirm previous data from a comparison of jugular venous and arterial levels of TxB 2 ." Our data also indicate that this increased release of TxB 2 can be prevented by pretreatment with ibuprofen.
These data support the conclusion that a product of cyclooxygenase metabolism, possibly TxA 2 , is involved in postischemic hypoperfusion. Our previous study had shown that an inhibitor specific for TxA 2 synthetase did not affect postischemic hypoperfusion, 19 a finding in agreement with results from other studies. 2425 The confounding factor regarding studies of TxA 2 synthetase inhibition is that the precursors of TxA 2 , the cyclic endoperoxides, may stimulate TxA 2 receptors. If true, these eicosanoids could produce physiologic effects identical to those of TxA 2 despite the absence of TxA 2 . Recently, a blocking agent (AH 23848) specific for TxA 2 receptors has been identified, 26 and its use should help to clarify the precise role of TxA 2 and TxA 2 receptors. The apparent beneficial effect of ibuprofen may relate to inhibition of the intravascular production of both TxA 2 and intermediate compounds that, like TxA 2 , have vasoconstrictor effects.
The release of the stable metabolite of PGI 2 from the cerebral circulation in the control group confirms previous data. 18 However, inhibiting production of intravascular PGI 2 was still associated with improved CBF in the ibuprofen-pretreatment group, which perhaps reflected limited importance of PGI 2 .
In summary: Pretreatment with 12.5 mg/kg ibuprofen ameliorated the brain hypoperfusion that followed a 10-minute period of global cerebral ischemia in dogs. The improved CBF was associated with a decrease in the release of TxA 2 from the cerebral circulation. The precise mechanism for the observed effect of ibuprofen is unclear, but it may be related to inhibition of the production of both TxA 2 and intermediate eicosanoid compounds that, like TxA 2 , have vasoconstrictor effects.
Further studies are necessary to clarify the role of cyclooxygenase metabolites in postischemic hypoperfusion and to determine if pharmacologic manipulation of eicosanoid synthesis or activity can improve neurologic outcome after global cerebral ischemia. 
